Country Overview
Key Facts
Number of Employees: Approximately 1,550
Main Brands:
Marlboro, Parliament, L&M, Muratti, Lark, Bond Street, Chesterfield, Lider
Welcome to Philip Morris/Sabanci, Philip Morris International’s (PMI) affiliate in Turkey. In 1984, PMI entered the Turkish cigarette market and in 1991, PMI established a joint venture with Sabanci Holding. Production of PMI brands began at the Philsa factory in Torbali shortly thereafter.
Today, nearly 730 employees work in this state-of-the-art manufacturing center, PMI’s fourth-largest production facility in the world. The Philsa factory produces a wide range of brands to meet Turkish adult smokers’ preferences including Marlboro, Parliament, L&M, Muratti, Chesterfield, Lark, Bond Street, and Lider.
Philip Morris/Sabanci actively supports charitable contributions programs in Turkey. One of our largest programs is to provide scholarships to students in need.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
Addiction
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Secondhand Smoke
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Effective Regulation
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.